Dr. Pascal Dabel, MD

Dr. Dabel practices at Laurel Canyon Dialysis in Sun Valley, California.

Dr. Dabel's NPI, 1033306592, was assigned on September 28, 2007. Dr. Dabel graduated from Tufts University School Of Medicine in 2006. Dr. Dabel holds California license A131011.

Dr. Dabel's primary practice is Laurel Canyon Dialysis, at 8987 Laurel Canyon Blvd, Sun Valley, CA 91352 in Los Angeles County. The practice phone is (818) 771-9950.

Dr. Dabel's primary practice is Laurel Canyon Dialysis in Sun Valley, California. Dr. Dabel is also affiliated with Pacifica Hospital of the Valley. The medical group on file is Kidney Consultants Medical Group. Dmand AI also links Dr. Dabel to 4 more hospitals, 4 dialysis centers, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dabel practices, 12 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Dabel's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Dabel is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Dabel's licenses on file in 4 states: California, Florida, Ohio and New York.

Dmand AI lists chronic kidney disease, fluid and electrolyte imbalances and parathyroid gland disorder among the conditions Dr. Dabel treats.

CMS data shows 3,727 Medicare services from Dr. Dabel across 13 procedure codes in 2024, for 582 Medicare patients. Medicare paid $520,361 for them.

CMS counts 582 Medicare patients who saw Dr. Dabel in 2026. The largest group is 65 to 74, with 173 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 71% are also on Medicaid. Their average risk score is 4.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dabel's median patient age at 69, with 47% women.

In 2026, Dr. Dabel wrote 1,116 Medicare Part D claims for 235 patients. 85% of them were for generic drugs. CMS names the drug for 947 of them, across 28 drugs with 11 or more claims each, at $165,702 in total drug cost. In 2023, CMS named 670 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Dabel for performance year 2026, reported as part of a group. Dr. Dabel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dabel as offering telehealth.

Dmand AI links 2 papers to Dr. Dabel, published from 2011 to 2016.

Dmand AI links Dr. Dabel to 4 clinical trials, 2 of them phase 3 studies. Conditions studied include Gout, Polycystic Kidney, Autosomal Dominant and Renal Insufficiency, Chronic. Amgen sponsors the most, 2.

CMS Open Payments shows 378 general payments to Dr. Dabel from 39 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 90% of the total. Amgen Inc. paid the most, $1,573.

Dmand AI lists 1 award for Dr. Dabel, most recently CMS Stage 1 2012 in 2012. Dr. Dabel serves on CAUTI Prevention and Pharmacy & Therapeutics.

Dr. Dabel graduated from Tufts University School Of Medicine in 2006.

Dr. Dabel is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.